

ARATANA THERAPEUTICS, INC.

Form S-8

March 13, 2019

As filed with the Securities and Exchange Commission on March 13, 2019

Registration No. 333-

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT UNDER  
THE SECURITIES ACT OF 1933

ARATANA THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	38-3826477
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)
11400 Tomahawk Creek Parkway, Suite 340	

Leawood, KS	66211
(Address of Principal Executive Offices)	(Zip Code)
Aratana Therapeutics, Inc. 2013 Incentive Award Plan	

(Full Title of the Plan)

Craig A. Tooman  
President and Chief Executive Officer  
Aratana Therapeutics, Inc.  
11400 Tomahawk Creek Parkway, Suite 340

Leawood, KS 66211

(Name and Address of Agent for Service)  
(913) 353-1000

(Telephone Number, including Area Code, of Agent for Service)

Copies to:

(913) 353-1000

Edgar Filing: ARATANA THERAPEUTICS, INC. - Form S-8

John C. Ayres, Esq.

General Counsel

Aratana Therapeutics, Inc.

11400 Tomahawk Creek Parkway, Suite 340

Leawood, KS 66211

(913) 353-1000

Jack Bowling, Esq.

Kelly L. Stout, Esq.

Stinson Leonard Street LLP

1201 Walnut Street, Suite 2900

Kansas City, MO 64106

(816) 842-8600

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b of the Exchange Act.

Large accelerated filer

Non-accelerated filer

Emerging Growth Company

(Do not check if a smaller reporting company)

Accelerated filer

Smaller reporting company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

---

CALCULATION OF REGISTRATION FEE

Title of Securities to be Registered	Amount to be Registered(1)	Proposed Maximum Offering Price Per Share	Proposed Maximum Aggregate Offering Price	Amount of Registration Fee
Common Stock, \$0.001 par value per share	1,203,369 shares(2)	\$3.74 (3)	\$4,500,600.06(3)	\$545.47

- (1) In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.
- (2) Consists of an additional 1,203,369 shares issuable under the Aratana Therapeutics, Inc. 2013 Incentive Award Plan pursuant to the terms of such plan.
- (3) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended, and based upon the average of the high and low prices of the Registrant's Common Stock as reported on the Nasdaq Global Select Market on March 8, 2019.
-

## EXPLANATORY NOTE

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 1,203,369 shares of the Registrant's common stock to be issued pursuant to Registrant's 2013 Incentive Award Plan and for which a Registration Statement of the Registrant on Form S-8 relating to the same employee benefit plan is effective.

## INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON FORM S-8

Except as set forth below, the contents of the Registration Statements on Form S-8 (File No. 333-189687, 333-193472, 333-203003, 333-210232, 333-216682 and 333-223653), filed with the Securities and Exchange Commission on June 28, 2013, January 21, 2014, March 25, 2015, March 15, 2016, March 14, 2017 and March 14, 2018, respectively, relating to the Registrant's 2013 Incentive Award Plan, are incorporated by reference herein.

### Item 8. Exhibits

Number	Description
4.1(1)	<u>Restated Certificate of Incorporation of the Registrant</u>
4.2(2)	<u>Amended and Restated By-Laws of the Registrant</u>
5.1	<u>Opinion of Stinson Leonard Street LLP, counsel to the Registrant</u>
23.1	<u>Consent of PricewaterhouseCoopers LLP</u>
23.2	<u>Consent of Stinson Leonard Street LLP (included in Exhibit 5.1)</u>
24.1	<u>Power of attorney (included on the signature pages of this registration statement)</u>
99.1(3)	<u>Aratana Therapeutics, Inc. 2013 Incentive Award Plan</u>

- 
- (1) Previously filed as Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-35952) filed with the SEC on July 3, 2013, and incorporated herein by reference.
  - (2) Previously filed as Exhibit 3.2 to the Registrant's Current Report on Form 8-K (File No. 001-35952) filed with the SEC on July 3, 2013, and incorporated herein by reference.
  - (3) Previously filed as Exhibit 99.1 to the Registrant's Registration Statement on Form S-8 (File No. 333-193472) filed with the SEC on January 21, 2014, and incorporated herein by reference.
-

## SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Leawood, State of Kansas, on this 13th day of March, 2019.

ARATANA THERAPEUTICS, INC.

By: /s/ Craig A. Tooman  
 Craig A. Tooman  
 President and Chief Executive Officer

## POWER OF ATTORNEY AND SIGNATURES

We, the undersigned officers and directors of Aratana Therapeutics, Inc., hereby severally constitute and appoint Craig A. Tooman and Rhonda L. Hellums, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Craig A. Tooman Craig A. Tooman	President, Chief Executive Officer and Director (Principal Executive Officer)	March 13, 2019
/s/ Rhonda L. Hellums Rhonda L. Hellums	Chief Financial Officer and Treasurer (Principal Financial and Accounting officer)	March 13, 2019
/s/ Wendy L. Yarno Wendy L. Yarno	Chairperson of the Board of Directors	March 13, 2019
/s/ Craig A. Barbarosh Craig A. Barbarosh	Director	March 13, 2019

Barbarosh, Esq. /s/ Laura A. Director Brege Laura A. Brege	March 13, 2019
/s/ David L. Director Brinkley David L. Brinkley	March 13, 2019
/s/ Irvine O. Director Hockaday Irvine "Irv" O. Hockaday, Esq.	March 13, 2019
/s/ Merilee Director Raines Merilee Raines	March 13, 2019
/s/ Lowell W. Director Robinson Lowell W. Robinson	March 13, 2019
/s/ Robert P. Director Roche Robert P. Roche	March 13, 2019
/s/ John Director Vander Vort John Vander Vort, Esq.	March 13, 2019

---